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Cancer stem cell (CSC) biology and tumor immunology have shaped our understanding
of tumorigenesis. However, we still do not fully understand why tumors can be contained
but not eliminated by the immune system and whether rare CSCs are required for tumor
propagation.
Long latency or recurrence periods have been described for most tumors. Conceptually,
this requires a subset of malignant cells which is capable of initiating tumors, but is nei-
ther eliminated by immune cells nor able to grow straight into overt tumors. These criteria
would be fulfilled by CSCs. Stem cells are pluripotent, immune-privileged, and long-living,
but depend on specialized niches. Thus, latent tumors may be maintained by a niche-
constrained reservoir of long-living CSCs that are exempt from immunosurveillance while
niche-independent and more immunogenic daughter cells are constantly eliminated.
The small subpopulation of CSCs is often held responsible for tumor initiation, metastasis,
and recurrence. Experimentally, this hypothesis was supported by the observation that
only this subset can propagate tumors in non-obese diabetic/scid mice, which lackT and B
cells.Yet, the concept was challenged when an unexpectedly large proportion of melanoma
cells were found to be capable of seeding complex tumors in mice which further lack NK
cells. Moreover, the link between stem cell-like properties and tumorigenicity was not sus-
tained in these highly immunodeficient animals. In humans, however, tumor-propagating
cells must also escape from immune-mediated destruction. The ability to persist and to
initiate neoplastic growth in the presence of immunosurveillance – which would be lost in
a maximally immunodeficient animal model – could hence be a decisive criterion for CSCs.
Consequently, integrating scientific insight from stem cell biology and tumor immunol-
ogy to build a new concept of “CSC immunology” may help to reconcile the outlined
contradictions and to improve our understanding of tumorigenesis.
Keywords: tumor-propagating cells, tumor immunology, tumor immunosurveillance, tumor dormancy, latency,
tumor immune escape, cancer stem cells, cancer stem cell immunology
INTRODUCTION TO TUMOR IMMUNOSURVEILLANCE
Cancer is caused by accumulating genetic alterations in a cell.
These lead to activation or multiplication of proteins promot-
ing cell growth and survival whereas proteins promoting cell
cycle arrest or cell death are lost or inactivated. Every day no
less than one million molecular lesions are thought to occur in
the DNA of a single cell (1). While most of these are instantly
repaired, the high number implies that very effective control mech-
anisms must exist to prevent the formation of tumors by mutant
cells. This includes both cell-intrinsic mechanisms, such as DNA
repair enzymes and tumor suppressor genes [comprehensively
reviewed by Hanahan and Weinberg (2)], and the cell-extrinsic
control function of the immune system, as first postulated by
Paul Ehrlich more than a century ago and systematically intro-
duced by Burnet in 1953 (3). Tumor immunosurveillance relies
on traits of malignant transformation that can be recognized by
innate and adaptive immune cells. As oncogenic stress induces
the upregulation of ligands for activating NK cell receptors (4)
and other immune stimulatory surface molecules, tumor cells
can be recognized and rejected by NK cells. This innate immune
response can further activate a targeted adaptive immune response
against antigens specifically expressed by lysed tumor cells and
thereby lead to T cell dependent tumor control. Such immuno-
genic antigens are either highly overexpressed in tumor cells or
even tumor specific (when caused by non-silent mutations that
have accumulated during malignant transformation) (5). Whole
genome sequencing data from lung cancer (6, 7), melanoma, and
lymphoblastoid carcinoma (8) genomes indicate that tumors can
harbor up to 50,000 somatic mutations of which few hundreds
affect protein-coding sequences. It is estimated that this will result
in about 7–10 new and unique MHC-binding peptides per HLA
allele (9).
Accordingly, innate immunity may constitute a first line of
defense, but long-term control is thought to depend on the sub-
sequent adaptive immune responses and on memory cells, which
also provide us with life-long protection against pathogens. The
detailed roles of different immune cells in tumor immunosurveil-
lance have been comprehensively reviewed recently (10, 11).
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Key molecules for tumor immunosurveillance as identi-
fied in knockout mouse models comprise interferon-γ (IFNγ)
(12), IL-12 (13) perforin (14, 15), TRAIL (tumor necrosis fac-
tor related apoptosis-inducing ligand) (16–19), and its corre-
sponding apoptosis-inducing receptors DR4 and DR5 (20), the
recombination activating genes RAG1 (21), and RAG2 (12), which
are required for T cell development, the T cell receptor (22), and
the activating NK cell receptor NKG2D (23). The loss of any of
these molecules results in more frequent or faster spontaneous or
carcinogen-induced tumorigenesis. The ability to evade immune
destruction was thus recognized as an additional hallmark of
cancer (24).
TUMOR LATENCY AND IMMUNE ESCAPE
Late recurrence indicates that tumor outgrowth can sometimes
be constrained over decades. Koebel et al. (13) elegantly demon-
strated that the immune system can control tumor outgrowth
without actually eradicating every malignant cell. By treating
immunocompetent mice with low doses of the carcinogenic com-
pound methylcholanthrene, they induced stable masses contain-
ing only very few malignantly transformed cells. However, when
CD4+ or CD8+ T cells were depleted even as late as 200 days
after chemical carcinogenesis, tumors started to grow. This indi-
cates that the immune system can control tumor growth and keep
pre-malignant lesions in a dormant state rather than completely
eliminating every transformed cell.
Correspondingly, immunocompromised humans such as
recipients of organ transplants (25–28) or AIDS patients (29–31)
have a significantly increased risk of cancer development, which
may be partially attributed to the loss of immunological con-
trol over preexistent malignantly transformed cells. Advanced age
remains the most important risk factor for tumor development
[recently reviewed by de Magalhaes (32)], which may be due to
a decline of immunosurveillance. While the stochastic increase in
the number of genetic alterations over time and the deterioration
of cellular repair mechanisms certainly contribute to this well-
known phenomenon, age-dependent defects in the immune sys-
tem (also termed “immunosenescence”) (33–35) are also likely to
facilitate tumor outgrowth. This is corroborated by the finding that
adoptively transferred spleen cells from young immunized mice
eliminate even large tumors whereas immune cells from old mice
are not protective (36). Further factors which may reduce the effi-
ciency of anti-tumor immune responses include non-recognition
of tumor antigens due to pre-established tolerance (37), evolution
of poorly immunogenic subsets of tumor cells and immuno-
suppression via accessory cells in the tumor microenvironment.
However, tumor-initiating cells need to escape from immunosur-
veillance even before a proper tumor microenvironment has been
established.
On cellular level, continuous genetic transformation can ran-
domly generate less-immunogenic malignant subclones. Lower
levels of activatory and/or higher levels of inhibitory NK cell recep-
tor ligands (38, 39) may enable these cells to survive in the presence
of the immune system. Also antigens toward which a specific T
cell immune response has been established may be lost (40, 41).
Furthermore, aggressive tumors are often characterized by low
levels of classical HLA class I molecules. Accordingly, those tumor
antigens, which are expressed, are poorly presented which limits
killing by CD8+ cytotoxic T lymphocytes (CTLs) (42). Never-
theless, a complete loss of ”self-MHC,” which would render cells
most susceptible for NK cell killing (11, 43–45) does not seem to
be the rule. A further important aspect is the active suppression of
NK and T cells in the tumor microenvironment where immuno-
suppressive cytokines or hormones are abundant. Cell surface
expression and/or secretion of immune-inhibitory non-classical
HLA class I molecules such as HLA-G and HLA-E also contributes
to local immune paralysis (42).
Physiologically, many of these factors are required for feto-
maternal immune tolerance. As immune-mediated destruction
of semi-allogeneic embryonic cells would preclude a successful
pregnancy, tolerance toward cells expressing “non-self” antigens is
essential for reproduction. This imposes certain limits to the strin-
gent elimination of altered cells. Unfortunately, the same tolerance
inducing strategies may also be used by cancer cells to overcome
immunosurveillance. Nevertheless, mechanisms to prevent tumor
growth still fulfill their evolutionary purpose by largely protect-
ing individuals from cancer until reproductive age or, ideally, until
their children (or even grandchildren) have become adults.
INTRODUCTION TO CANCER STEM CELLS
Tissue-specific stem cells have been described in many tissues
prone to cancer, including breast (46, 47), lung (48), prostate
(49–51), intestine (52, 53), and many others. They are excep-
tionally long-lived and can perpetually self-renew. They further
give rise to progenitor cells, which are more restricted in their
developmental potential, but capable of undergoing rapid cell
divisions. The respective daughter cells then further differenti-
ate into mature tissue-specific cells, which contribute to growth,
tissue homeostasis, and wound healing (Figure 1A) [reviewed by
Ref. (54, 55)].
This cellular hierarchy within a tissue has been studied most
extensively in the hematopoietic system. Here, long term and short
term stem cells, multipotent and lineage-committed progenitor
cells, precursors, and fully differentiated cells have been well char-
acterized based on their functional properties and on cell surface
markers [reviewed by Orkin (56)]. Among these, pluripotent stem
cells tend to cycle very slowly while the bulk of blood cells origi-
nate from various frequently dividing progenitor cell populations
(57, 58). In adult mice, a population of quiescent or dormant
hematopoietic stem cells has been described to undergo only about
five divisions during the lifespan of a mouse (59).
Because of their longevity, pluripotency, and seemingly unlim-
ited potential to undergo cell divisions, stem cells have long been
suspected to be the culprits for tumor formation (60). It is indeed
much more likely that a stem cell, which persists for decades
in a given tissue, rather than a short-lived differentiated cell,
can accumulate numerous mutations as required for malignant
transformation (61, 62) (Figures 1B and S1 in Supplementary
Material). Moreover, the presence of highly diverse cancer cell
populations both in tumors and metastases indicates that their
cells of origin are pluripotent. In fact, Kleinsmith and colleagues
showed already in the 1960s that some teratocarcinoma cells are
capable of seeding highly heterogeneous tumors even if only sin-
gle cells are transplanted (63). Recently, it was shown that even
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FIGURE 1 | Stem cells and progenitor cells in tissue homeostasis,
tumorigenesis, and tumor recurrence. (A) During organogenesis or in
response to tissue damage, resting stem cells (SCs) are induced to undergo
asymmetric divisions that produce further differentiated progenitor cells
(PCs). Progenitor cells can quickly regenerate tissue by first undergoing a
limited number of symmetric cell divisions. The generated daughter cells can
then further differentiate to acquire organ-specific functions while generally
losing the ability to reenter the cell cycle. (B) Stem cells are exceptionally
long-lived, pluripotent, and can undergo an unlimited number of cell divisions.
Therefore, they may accumulate more mutations than other cells and are thus
stochastically more likely to initiate a tumor. These mutations are passed on to
progenitor cells, which may drive tumor outgrowth as they cycle much faster
by nature. (C) Stem cells and CSCs are highly resistant to chemotherapeutic
agents and irradiation, which explains why these cells might selectively
survive cytoreductive therapy. Therefore, these cells may cause cancer
recurrence years or decades later.
some blood vessels within glioblastoma are derived from tumor
cells (64). This strikingly illustrates the remaining differentiation
potential of tumor-initiating cells.
Clinical observations from cancer patients teach us that
tumor recurrence may still occur years or decades after a
successful-appearing treatment. In this context, a recent sequenc-
ing study on acute myeloid leukemia showed that cells collected at
the time of the initial diagnosis and during relapse were both
closely related to stem cells. Surprisingly, cells collected after
relapse had often undergone fewer cell divisions than cells col-
lected at first diagnosis (65). This suggests that the relapsed disease
originated from Cancer stem cells (CSCs), which had been largely
quiescent during the initial tumor burst, but which survived tumor
eradication without losing their malignant potential. Indirectly,
this also confirms the existence of a long-lived and multipotent
subpopulation of cancer cells, which is highly resistant to radio-
and chemotherapy (Figure 1C) and too small to be detected by
common screening methods.
Similar to non-malignant stem cells, CSCs are thought to cycle
much more slowly than cancer progenitor cells (CPCs). This could
explain their resistance toward drugs directed against dividing
cells. Additionally, many stem cells can minimize intracellular drug
levels via expression of ABC (ATP binding cassette) transporters
(66). Accordingly, chemoresistance is expected to be an inherent
trait of CSC even before the onset of therapy. Furthermore, stem
cells and cancer cells share decreased p53 activity and increased
telomerase activity (67).
Still, resistant CSCs are not necessarily the main drivers of
rapid tumor outgrowth. While acquisition of specific mutations
may alter the replicative behavior of these quiescent and niche-
dependent cells (68), homeostatic, and presumably also neoplastic
tissue growth depends mainly on niche-independent progenitor
cells which divide much more rapidly. In this manuscript, the term
CPC is used for the malignant counterparts of such rapidly divid-
ing and lineage-committed cells. As these cells inherit genomic
mutations accumulated by stem cells, malignantly transformed
stem cells will give rise to malignantly transformed committed
progenitor cells, which can then drive tumor growth. Luminal
progenitor cells deleted for the tumor suppressor gene Brca1 were
thus shown to seed basal-like breast cancer in mice (69, 70). Like-
wise, prostate cancer can be initiated by basal progenitor cells,
which have been virally transfected with oncogenes (71). Obvi-
ously, CPCs may not only inherit mutations, but also accumulate
“first genetic hits,” which likely contributes to clonal evolution and
to the heterogeneity typically found in late stage tumors.
THE CANCER STEM CELL HYPOTHESIS – AMBIGUITIES AND
CRITICISM
Cellular differentiation states are difficult to categorize. While
omnipotent embryonic stem cells (ESCs) and terminally
differentiated cells represent the two ends of the spectrum, numer-
ous gradual transitions exist in between. Defining clear-cut cate-
gories is even more difficult in the tumor context where cellular
functions and markers may be randomly altered due to mutations.
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Distinct stem cell markers have been described for CSCs, but these
only help to define CSCs within a certain tissue. In an attempt
to define the unifying functional characteristics of a CSC, a panel
at the American Association of Cancer Research (AACR) meeting
suggested in 2006: “A CSC is a cell within a tumor that possesses
the capacity to self-renew and to cause the heterogeneous lineages
of cancer cells that comprise the tumor” (72). We consider this
definition to be insufficient for several reasons:
1) De-differentiation. By now, a considerable body of evidence
indicates that lineage-committed differentiated cells and prog-
enitor cells can de-differentiate into multipotent stem cells.
While induced pluripotent stem cells [iPS cells as first intro-
duced by Takahashi and Yamanaka (73)] are typically generated
by artificially introducing defined transcription factors into
differentiated cells, de-differentiation can also occur spon-
taneously (74) or in response to external stimuli (75, 76).
Accordingly, both tissues and tumors may not be organized
in a strictly hierarchical manner with few stem cells on the
apex, but rather in a more dynamic way with constantly dif-
ferentiating and de-differentiating cells (77, 78). Likewise, a
fairly constant percentage of CSC-like cells can be found to co-
exist with basal or luminal progenitor cells in some established
tumor cell lines. These populations can be isolated. However,
if cultured for a few days, each of them will regenerate the
depleted populations and an equilibrium containing almost
identical proportions of all three original differentiation states
is quickly reestablished (77).
The most prominent example of physiological transdiffer-
entiation is the so-called epithelial to mesenchymal transition
(EMT) (79–81) during which epithelial cells acquire stem cell-
like properties. Interestingly, in breast cancer or melanoma
EMT can be induced by CD8+ T cells (77, 80). Accordingly,
there appears to be more plasticity within the cellular hierarchy
than previously anticipated, especially in tumors.
2) The frequency of tumor-propagating cells depends on the
respective animal model. For melanoma, CSC markers, fre-
quencies, and their role in tumorigenesis were investigated
in considerable detail. CD20 (82), CD133 (83), ABCG2 (83),
MDR1 (84), or CD271 (85) have all been described as poten-
tial markers for melanoma cells with increased tumorigenic
potential as assessed in non-obese diabetic (NOD)/severe com-
bined immune-deficient (scid) mice. With about one CSC
in 106 melanoma cells, these CSCs constitute only a minute
subset of all tumor cells (86). However, in a highly debated
(87, 88) article, Quintana et al. (89) reported that about 27%
of highly aggressive melanoma cells were capable of induc-
ing tumors in interleukin-2 receptor gamma chain deficient
(Il2rg−/−) NOD/scid (NSG) mice, which do not only lack
T and B, but also NK cells. Thus, the proportion of tumor
cells, which can self-renew and seed heterogeneous tumors
in highly immunodeficient mice may be much higher than
previously anticipated. This raised the question whether the
small subpopulation of CSCs is of any clinical relevance (86).
In a later study, the same authors proposed that most
melanoma cells may reversibly express stem cell markers (90).
They argue in favor of clonal evolution and negate any kind of
hierarchical organization within a tumor cell population, thus
refuting the basic idea underlying the CSC hypothesis. Accord-
ingly, the term CSC is avoided by some authors and replaced
by more descriptive alternatives such as cancer-initiating cell,
tumor-propagating cell or metastasis-initiating cell. In our
opinion, however, this approach has not helped to simplify
matters, especially since suitable markers and physiologically
correlating cell populations are ill-defined.
We believe that the ability of differentiated cancer cells to
de-differentiate into CSCs may partly reconcile these conflicting
findings. Moreover, it should be noted that these data were gener-
ated in mice with very different immunological properties. Thus,
a unique and functionally most relevant criterion shared by stem
cells and CSCs, namely their lack of immunogenicity, should be
considered.
IMMUNOLOGICAL PROPERTIES OF CSCs
Unfortunately, our knowledge about specific immunological
properties of distinct CSC populations is still limited. It is,however,
clear that high levels of anti-apoptotic proteins like bcl-2, bcl-xL,
or survivin do not only protect CSCs against chemotherapeutic
drugs (91), but also increase resistance toward apoptosis-inducing
immune effectors like T or NK cells. In this context, the PI3K/Akt
pathway seems to be of particular relevance: it is not only a known
mediator of chemoresistance and CSC renewal (92), but was also
found to be involved in tumor immune escape (93). Likewise,
the oncogenic growth factor receptor HER2/neu (which activates
PI3K/Akt signaling) does not only deliver pro-survival signals (94).
HER2 does also interfere with antigen processing and presenta-
tion (95, 96) and it was reported as crucial for the maintenance of
CSC in luminal breast cancer (97). Thus, mechanisms which were
mainly thought to mediate chemoresistance in CSC may also con-
fer cross protection against immune-mediated tumor eradication.
In the aggressive melanoma cell line A375, Schatton and
Frank also found the immunogenic tumor-associated antigen
MART-1 (melanoma antigen recognized by T cells) to be only
expressed on differentiated melanoma cells, but not on malignant
melanoma initiating cells (MMICs). MART-1-specific T cells thus
cannot eliminate MMICs (98). Reim et al. have further shown
that CD44high/CD24low breast CSCs selectively escape from NK
cell mediated killing and trastuzumab-dependent ADCC (99).
While these findings explain the difficulties in targeting CSCs
with immune cells, stem cell-like cells are not only poor tar-
gets for immunosurveillance. They also actively suppress immune
responses (100), which may be crucial during tumorigenesis (101).
Breast CSCs (102) and glioblastoma stem cells (103) secrete more
TGF-β as compared to normal tumor cells. Colon CSCs are fur-
ther known to secrete Interleukin 4 (104), which promotes drug
resistance (104) and inhibits anti-tumor immune responses (105).
CSCs also express CD200 (106), a molecule that inhibits myeloid
cells and could therefore play a major role in tumor immune escape
(107,108). Immunological properties of CSCs in solid tumors have
also been recently reviewed by Maccalli et al. (109).
More is known about molecular immunological properties
of physiological stem cells. ESCs express little classical antigen-
presenting MHC class Ia molecules and no MHC class II molecules
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and will thus be poor antigen presenters for T cells. Additionally,
they express only low levels of ligands for the activatory NK cell
receptor NKp44 and no ligands for NKp30, NKp46, and CD16
(110). Among inhibitory signals, HLA-G (111) is highly expressed
by both embryonic (112) and mesenchymal stem cells (MSCs)
(113). Thus, studies describing higher MHC class I expression on
stem cells may have failed to distinguish between immunogenic
MHC class Ia (HLA-A, -B, -C) and immunosuppressive MHC
class Ib (HLA-E, -F, -G) molecules. MHC class II or costimulatory
molecules such as CD40, B7-1 (CD80), or B7-2 (CD86), which
can also support T cell interactions with non-lymphoid cells (114)
have not been found on MSCs (115–117).
T cell proliferation, macrophage activation, and Th1 responses
can further be suppressed by prostaglandin E2 (PGE2), which is
secreted by MSCs (118, 119). After exposure to IFN-γ, MSCs also
upregulate indoleamine 2,3-dioxygenase (IDO), which metabo-
lizes tryptophan into immunosuppressive kynurenines. The con-
comitant tryptophan depletion also has a profound inhibiting
effect on T cells (120). Via secretion of hepatocyte growth factor
(121), MSCs can further induce tolerogenic dendritic cells and reg-
ulatory T cells (122). Consequently, MSCs show beneficial effects
in autoimmune disease models (123–125).
To summarize, stem cells and CSCs both express numerous
and diverse membrane-bound and soluble factors (Figure 2),
which enable these cells to efficiently modulate immune responses
and which protect them against immune-mediated destruction
in a way that is unrivaled by further or fully differentiated cells.
Strikingly, mouse ESCs and human MSCs have even been shown
to survive for weeks and to engraft in immunocompetent rats
(126) and sheep (127, 128). The immunomodulatory potential of
MSCs is now exploited clinically to counteract graft-versus-host
disease (129) and to promote allograft acceptance upon solid organ
transplantation (130).
As the immune system is incapable of eliminating allogeneic
or even xenogenic stem cells, the comparatively few mutations
acquired by CSC are unlikely to cause immune-mediated rejection.
Thus, stem cells likely represent a unique compartment in which
oncogenic mutations can accumulate without being detected by
the immune system.
IMMUNE PRIVILEGE – THE MISSING CSC CRITERION?
The question whether or not all cancer cells are equally capa-
ble of seeding tumors obviously depends also on their ability
to escape from destruction by the innate or adaptive immune
system. This essential difference, however, may not be observ-
able in a mouse model lacking functional T, B, and NK cells,
such as the NSG (131) mice used by Quintana et al. (89). The
conflicting data on the frequency of melanoma initiating cells
can thus easily be explained by accepting that CSCs are much
less sensitive toward tumor immunosurveillance than more dif-
ferentiated cells. While NK cells in NOD/scid mice may clear
more differentiated cancer cells (Figure 3B), they cannot elim-
inate immunosubversive human CSCs (Figure 3A). Thus, non-
CSC-like cancer cells may replicate endlessly in vitro whereas
only CSCs will seed tumors in these mice. NK cell-deficient
NSG mice can, in contrast, neither eliminate CSCs (Figure 3C)
nor more differentiated cancer cells, which would then also
become capable of seeding tumors (Figure 3D). Their recently
FIGURE 2 | Factors and pathways contributing to the low
immunogenicity of stem cells and CSCs. Membrane-bound (solid line) and
soluble factors (dotted lines) implicated in immunotolerance toward stem cells
and CSCs are schematically depicted. These include antigen-presenting and
immunostimulatory molecules (orange) expressed at low levels and abundantly
expressed immunosuppressive factors (blue) (see main text for references).
Immune effector cells impaired by these signals are shown in red whereas
tolerogenic immune cells, which may be stimulated are displayed in green.
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FIGURE 3 |Tumor-propagating capacity depends on immunological
properties of injected cancer cells and on the respective mouse
model. NK cells in NOD/scid mice are likely incapable of eliminating CSCs
due to their low immunogenicity (A). More differentiated cancer cells
expressing ligands for activating NK cell receptors and fewer
immunosuppressive molecules may, however, be recognized and
eliminated by host NK cells (B). In NOD/scid IL2rg−/− (NSG) mice, which
also lack NK cells, both poorly immunogenic CSCs (C) and further
differentiated cancer cells (D) can seed tumors, as malignant progenitor
cells may also possess enormous proliferative capacity.
discovered ability to de-differentiate may then further facilitate
tumor propagation.
A maximally immune-deficient mouse may therefore demon-
strate the malignant potential of differentiated cancer cells in the
complete absence of immunosurveillance, an aspect that may have
been underestimated in the original CSC theory. We, however,
wonder how relevant NSG mice can be for understanding tumor
initiation (and thus tumor-initiating cells) in patients. While stem
cell experts tend to favor the most completely immunodeficient
animal model available, the most relevant subject of transla-
tional cancer research is the immune-competent human subject
afflicted by a malignant disease. The ability to propagate tumors
should therefore best be tested in models possessing a functional
immune system. Furthermore, as implied by studies performed
in NOD/scid mice (132–134), the ability to continuously seed
tumors in presence of (residual) immunosurveillance may be a
most relevant functional criterion for CSCs.
Consequently, tumor initiation may better be analyzed in
congenic or syngenic animals rather than in immunodeficient
xenograft models. Limitations arise from the fact that all cells
contained in transplantable syngenic tumor cell lines have evi-
dently undergone immunoediting in vivo before the cell line could
be derived. Accordingly, the proportion of immune-refractory,
tumor-seeding cells may be quite variable: with B cell lymphoma
cells, for example, inoculation with 10 unsorted cells was suffi-
cient to induce lethal lymphomas within a few weeks, irrespective
of expression of the stem cell marker CD93 (135). In the 4T1
mammary carcinoma cell line, however, exclusion of the stem cells
(Hoechst 33342 side population) by cell sorting greatly reduced
both tumor take and tumor load, and most animals injected with
8× 103 non-CSC remained tumor-free (136). Thus, the frequency
of CSCs can differ widely depending on the respective tumor.
TUMOR IMMUNOEDITING – THE MODEL AND UNRESOLVED
QUESTIONS
The immune privilege of CSCs may not only be relevant for the
quantification of tumor-propagating cells, but could also help to
elucidate ambiguities in tumor initiation and immune escape.
The complex interactions between tumors and the immune sys-
tem have been described by a model which differentiates between
three phases of tumor immunoediting: elimination, equilibrium,
and escape (137). There is now solid scientific evidence for the
existence of all three phases and this model nicely correlates with
clinical observations (10).
During the elimination phase, tumors may be successfully
detected and destroyed by the innate and adaptive immune system,
which results in the reestablishment of healthy tissue. If, however,
some tumor cells escape from elimination, a dynamic equilibrium
between tumor growth and immunological elimination of malig-
nant cells was proposed to emerge. While tumor outgrowth is still
constrained, elimination of tumor cells remains incomplete, which
allows for mutational diversification and Darwinian selection to
occur. This latency phase may persist for decades and may be func-
tionally similar to tumor dormancy, the time between an initially
successful anti-tumor therapy and tumor recurrence, which can
also span decades (138). When ultimately one clone arises that is
capable of escaping from a functional immune system, it may form
a clinically overt tumor and initiate the escape phase.
However, for the equilibrium to be reached, this model requires
“not yet immunoedited” cancer cells to survive the early elim-
ination phase. Furthermore, it is not clear why cells, which
can be immunologically constrained in equilibrium for decades,
are not simply cleared by an adaptive immune response. Nor-
mally, expanded and activated CTLs efficiently eliminate cells
expressing their cognate antigen whereas cells that have lost all
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immunologically relevant antigens could directly grow into overt
tumors.
Based on these considerations, latency requires the existence
of a poorly immunogenic sub-pool of cancer cells, which escape
from targeted immune responses, which can give rise to new can-
cer cells, but which are initially incapable of growing into massive
tumors. Instead, these cells apparently persist for months, years, or
even decades within tissues as dormant tumor cells. In our opinion,
multipotent stem cells and CSCs,which are not only long-lived,but
also exceptionally well protected from immune-mediated destruc-
tion, and largely confined to stem cell niches (68, 139), would
meet all these criteria. By considering the immunological prop-
erties of CSCs, a new refined concept of tumor immunoediting
can thus be proposed (Figure 4 and more detailed in Figure S1 in
Supplementary Material).
IMPLEMENTING CSCs IN THE CONCEPT OF TUMOR
IMMUNOEDITING
When oncogenic mutations occur in fully or partially differenti-
ated cells, activatory NK cell receptor ligands are induced (4) and
tumor antigens are presented via MHC class Ia. Thus, altered cells
may be readily detected and eliminated by the immune system.
Failure may be due to de-differentiation of mutated cells.
If, instead, an oncogenic mutation occurs in a poorly immuno-
genic stem cell, escape from immunosurveillance is much more
likely. However, their dependence on stem cell niches may prevent
mutated stem cells from growing into overt tumors. Upon asym-
metric division, a more differentiated and more immunogenic
daughter cell will be generated, which would then be subjected to
immunosurveillance. As the other daughter cell will maintain stem
cell characteristics, a robust equilibrium would emerge. Recent
findings indicate that AML finally arises from such pre-malignant
stem cells (140).
During this latency period, stochastic genetic and epige-
netic changes may accumulate within the reservoir of non-
immunogenic stem cells. Mutations in coding regions may gen-
erate new immunogenic peptides that would be presented on
MHC molecules of malignant daughter cells. Such neoanti-
gens may support immunosurveillance by providing further
tumor antigens and, ideally, enabling tumor clearance. How-
ever, if CSCs are not eliminated by the immune system, the
low frequency of niche-confined, mutated stem cells, and their
low rate of cell divisions would still prevent the formation of
a clinically relevant tumor as long as their daughter cells are
subjected to immunosurveillance. Accordingly, the immune sys-
tem could constrain a sub-clinical malignant disease in life-long
equilibrium.
FIGURE 4 | Proposed role of CSCs in tumor immune escape. Elimination
(Left): malignant transformation requires oncogenic mutations (flash) to
accumulate within an individual cell. If such mutations occur in a
differentiated cell, this cell will upregulate activatory NK cell receptor ligands
and present tumor-specific peptides via MHC class Ia molecules (both
orange). Thus, these cells can be detected and eliminated by the immune
system, leading to restoration of normal tissue. Equilibrium (Center): stem
cells (SC) are long-lived and express a multitude of immunosuppressive
factors (dark purple). Hence, they may accumulate oncogenic mutations
without being cleared by the immune system. However, CSCs are initially
confined to stem cell niches (green) and limited to asymmetric divisions.
More differentiated daughter cells inherit all malignant mutations, but are
more immunogenic and could thus be eliminated by the adaptive immune
system. Thus, a robust equilibrium may emerge. Escape (Right):
mechanisms contributing to tumor immune escape include defects in tumor
immunosurveillance, immunoediting, or the expansion of CSCs. The
immune system may lose its ability to constrain tumors due to aging,
immunosuppressive therapies, diseases or other factors. Immunoediting
describes the evolutionary adaptation of individual tumor subclones to the
selection pressure exerted by the immune system. It will ultimately lead to
expansion of less-immunogenic or more immunosuppressive subclones.
Non-immunogenic CSCs may further acquire the ability to expand
independently of their niches, which may lead to the outgrowth of poorly
differentiated tumors.
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Table 1 | A grossly schematic overview summarizing characteristic properties and functions of stem cells, progenitor cells, and differentiated
cells and their malignant counterparts.
Properties promoting tumor growth are shaded in red whereas traits that limit the malignant potential are highlighted in green.Though the actual characteristics vary
significantly between different tissues and tumors, common tendencies were sought. Some selected references are provided, and more are given in the main body
of the manuscript. When no representative reference could be found in the literature, this variability is indicated (var.). Where no data were available, an estimate is
given (CSC, cancer stem cell; CPC, cancer progenitor cell; diff. CC, differentiated cancer cell).
However, once tumors become clinically apparent immuno-
surveillance has failed. This can be due to a weakening of the
immune system caused by aging, to therapeutic immunosuppres-
sion or to disease. In this case, also moderately immunogenic
tumor cells may propagate. Alternatively, cancer cells may actively
attenuate immunosurveillance (immunosubversion) by secretion
or expression of immunosuppressive factors (11) or by recruit-
ment of accessory cells, which locally suppress the immune system
(141, 142). Furthermore, genetic alterations may result in reduced
expression of antigens that are targeted by the immune system
(immunoselection). Other factors allowing for the rapid growth
of more differentiated cancer cells include the loss of the antigen
processing and presentation machinery (143) or the loss or shed-
ding of ligands for activatory NK cell receptors (144). Importantly,
non-immunogenic long-lived CSCs provide an evolutionary play-
ground for mutations to accumulate until an immune escape
phenotype has emerged.
Expansion of immune-evasive CSCs represents a further pos-
sibility for immune escape. This mechanism may predominate in
poorly differentiated tumors, which tend to be more aggressive
and more difficult to treat (145). Alterations in cell signaling path-
ways are known to enable CSCs to grow outside of their niches
(68). Interestingly, signals that promote stem cell self-renewal
and expansion (146) are also frequently activated in cancer as
evidenced by alterations in the notch, wnt, and sonic hedgehog
pathways (147–149).
Oncogenic mutations may also increase the frequency of cell
divisions in otherwise fairly quiescent stem cells (150) or inhibit
differentiation in the respective daughter cells (151, 152). Fur-
thermore, CSC proliferation may be promoted by conditions like
chronic inflammation, which triggers physiological stem cell divi-
sion. As these mechanisms are not mutually exclusive, increased
cell division in CSCs will also increase the risk for emergence of
less-immunogenic and more aggressive subclones.
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IMPLICATIONS OF “CANCER STEM CELL IMMUNOLOGY”
Stem cell research has helped to understand tumor initiation, het-
erogeneity, and drug resistance, while immunological knowledge
has provided a framework for apprehending mechanisms that nat-
urally limit tumor growth. Consolidating insights from these two
different scientific fields may further help to explain phenomena
which are still poorly understood.
As discussed in this opinion article, we propose that pluripo-
tency, immortality, and an apparently unlimited potential to
undergo cell divisions may be insufficient criteria for distinguish-
ing CSCs from other cancer cells. In the tumor context, partly
differentiated cells may also acquire these properties through
mutations or de-differentiation processes. However, the unique
immunological properties of stem cells and CSCs may help to
further discriminate these cells from the tumor bulk (Table 1).
Experimental evidence supporting this novel perspective may be
drawn from model-dependent differences regarding the respective
frequencies of tumor-initiating cells. This may best be explained
by considering the different levels of immunogenicity coexisting
within the same tumor. In addition, CSCs excellently complement
current models of tumor immune escape. They can be seen as
highly resistant and long-lived units of Darwinian selection, which
accumulate mutations and undergo immunoediting over decades.
Thus, they can either remain dormant or represent an almost
invincible backbone of tumorigenesis which links “the three e’s
of cancer immunoediting”: elimination, equilibrium, and escape,
i.e., tumor recurrence.
Yet what are the clinical implications if CSCs are not only
highly resistant to chemo- and radiotherapy (153) but also to
anti-tumor immune responses? Strategies to specifically target
CSCs for elimination (154, 155) or to induce differentiation (156)
would obviously be most desirable. However, none of the current
approaches shows a high selectivity for CSCs over non-malignant
stem cells. Therefore, therapies that efficiently and selectively elim-
inate CSCs are still far from clinical application. Still, accepting that
we are currently unable to eradicate CSCs is far from accepting
defeat in the war on cancer. Instead, by accepting these limita-
tions one can rather prioritize strategies, which are more likely
to work. These include, on the one hand, the indirect targeting
of CSC via the tumor stroma, which represents a niche for CSCs
(157–160). On the other hand, containment and control of CSCs
to maintain tumors in the equilibrium phase may be a realistic
clinical aim. This, however, depends on the incessant function-
ality of the immune system (161). Beneficial effects of radio- or
chemotherapy, which can destroy some tumor cells (but presum-
ably not the CSC) may thus largely depend on immune responses
induced by provision of danger signals and by liberation of anti-
gens from damaged tumor cells (37, 162, 163). Strengthening of
cancer immunosurveillance by vaccination strategies or by directly
activating the immune system (164–166) may support such a
response and thus be effective in preventing tumor recurrence over
prolonged periods of time (167, 168). Adjuvant immunotherapy
might hence be advisable when a successful-appearing treatment
has reduced overt cancer to minimal residual disease (which likely
represents an immunologically sustained equilibrium). Overag-
gressive treatment modalities are, however, strongly immunosup-
pressive and may be detrimental. In fact, a comparatively mild
metronomic chemotherapy may often be more effective (169, 170)
than application of the maximum tolerated dose, which still fails
to eliminate the seed of the evil but enables the outgrowth of
more differentiated malignant cells. Assuming that CSCs repre-
sent moving targets, which need to be controlled throughout the
whole life, we need to learn how the highly dynamic and adaptable
forces of our immune system can best be used in the war on can-
cer. Fortunately, first studies are showing the potential of cancer
immunotherapy in clinical reality.
Last but not least, an improved understanding of the mech-
anisms which enable either tumor control or escape may help
to devise suitable therapeutic strategies. We thus hope that the
still speculative, but hopefully coherent conceptual framework
outlined in this brief article will stimulate further research in
“CSC immunology.” In the best case, a mutual exchange of ideas
could not only inspire both the CSC and the tumor immunology
community, but eventually also lead to some benefit for patients
who depend on a wisely chosen therapy.
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